Aarti Pharmalabs Ltd
Aarti Pharmalabs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.
From Aarti Pharmalabs Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years.
- CDMO vertical is expected to grow at a robust 40%-50% next year (FY2027), driving higher value growth.
- Xanthine segment aims to achieve around Rs.1,000 Crores revenue in FY2027, showing strong volume and value growth.
- API/intermediates segment is expected to surpass FY2025 revenue levels (approx. Rs.700-770 Crores) in FY2027, recovering from previous degrowth due to inventory and price erosion issues.
- Ramp-up of new capacities (Atali and Xanthine expansion) to contribute meaningfully to revenues and EBITDA starting from FY2027 Q2 onwards.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.
- Capex for dedicated manufacturing block is included but the exact amount is still being finalized.
- Atali plant expansion to continue with one new block per year, focusing more on brownfield expansions going forward to reduce capex intensity and speed up ramp-up.
- Xanthine derivative capacity to increase from 6,000 to 9,000 metric tons per annum by gradual ramp-up next few quarters.
- Steroid and anticancer blocks at Tarapur Unit-4 are undergoing debottlenecking and brownfield expansions in FY2027.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company currently has 21 active CDMO customers, a number steady over the last five quarters.
- Engagements with these customers are ongoing for newer projects, indicating pipeline development.
- In 2025, there was a slowdown in inquiries due to global uncertainties, but the situation has stabilized with increasing inquiries now.
- The management mentions having long-term and near-term understandings with customers regarding volumes for new capacities, indicating good visibility on future orders.
- Capex decisions for custom-built facilities are based on sensible forecasts from customers.
- Large projects tend to have one or two deliveries per year, leading to inventory buildup before delivery.
2 more points management made on order book & pipeline
Aarti Pharmalabs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹583 Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Aarti Pharmalabs Ltd Q4 FY26 results?
The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.
What is Aarti Pharmalabs Ltd share price analysis?
Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Pharmalabs Ltd planning capital expenditure?
Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.
Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.